Illumina, Inc. (ILMN) has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1.3 upgrade to elevate sequencing performance and advance data quality.In addition, the new NovaSeq X 25B 100 and 200-cycle kits are now available under Illumina's brand following the company's acquisition of Fluent.ILMN Stock’s Likely Trend Following the NewsAfter yesterday’s announcement, Illumina shares edg ...

Now in the market for the first time, the single-flow-cell NovaSeq X Sequencing System offers the same high-quality flow cells and speed as the NovaSeq X Plus Sequencing System—Illumina's most rapidly adopted and utilized high-throughput sequencing platform to date—at a more accessible cost for labs with lower volume. The sequencers began shipping in December, and simultaneously the company introduced the software v1.3 upgrade for the NovaSeq X Series to elevate sequencing performance and advance data quali ...

Illumina, Inc. (NASDAQ:ILMN) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon. I'm Vijay Kumar, a life science device analyst here at Evercore. Pleasure to have with us Illumina. We have Ankur Dhingra, CFO; and from Investor Relations, we have Salli Schwartz. Ankur, Sall ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina’s updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previo ...

Illumina, Inc. (NASDAQ:ILMN) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody. I'm Doug Schenkel. I'm the lead analyst for the tools, diagnostics and labs effort here at Wolfe Research. Thanks for being here today and listening in on the web. It's my pleasure to welcome Ankur Dhingra, the CFO of Illumina; and also ...

Illumina, Inc. (ILMN) is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to enable comprehensive genomic profiling (CGP) of tumors will be presented at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia, on Nov. 21. One of the customers having early access to TSO 500 v2 emphasized the relevance of the assay's new features to clinical research lab ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Score ...

Have you looked into how Illumina (ILMN) performed internationally during the quarter ending September 2024? Considering the widespread global presence of this genetic testing tools company, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. F ...

SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) 7th Annual Evercore HealthCONx Conference on December 3, 2024Fireside chat at 10:20am Pacific Time (1:20pm Eastern Time)For each conference, the webcast can be accessed through the Investor Info section of Illumina's website at i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 29, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporat ...